Convergence Pharmaceuticals has commenced phase II of a concept study of novel, small molecule, state-dependent calcium channel blocker CNV2197944 to treat pain related to diabetic peripheral neuropathy (DPN).

The randomised double-blind, placebo-controlled, two-period, two-treatment crossover study is designed to evaluate the efficacy and safety of a dose regime of CNV2197944 75mg three times a day against a placebo in patients with DPN.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The trial’s primary endpoint is to study the effect of repeat oral dosing of CNV2197944 on the pain experienced in DPN after three weeks, compared to the baseline, as measured by the Pain Intensity Numeric Rating Scale.

Convergence Pharmaceuticals chief executive officer Clive Dix said: "We have begun running a second proof of concept trial with CNV2197944 in neuropathic pain and are already excited about potential results."

Designed to selectively inhibit highly-active Cav2.2 channels, CNV2197944 has already completed safety and toxicology studies demonstrating its safety margin and tolerability.

"Based on the known pre-clinical and clinical profile of CNV2197944 and the data we have seen so far, we believe it will be a safer, more effective treatment for chronic pain, with a potentially better tolerability profile and wider therapeutic index than currently available treatments," Dix added.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Results from the study, which is being conducted by Convergence on behalf of Calchan, are expected to be presented in the second half of 2014.

Calchan is a part of Convergence Pharmaceuticals and holds the proprietary rights to CNV2197944.